SCM
DFTX

Superstring Capital Management’s Definium Therapeutics DFTX Stock Holding History

Superstring Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.64M Sell
351,461
-73,741
-17% -$1.25M 4.75% 6
2025
Q4 		$5.69M Buy
+425,202
New +$5.26M 3.05% 10

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Superstring Capital Management's DFTX Position: Q1 2026 in Review

Superstring Capital Management reduced its Definium Therapeutics (DFTX) stake by 17% in Q1 2026, selling an estimated $1.25M and leaving 351,461 shares worth $6.64M. The position accounts for 4.75% of the portfolio, ranked #6.

Superstring Capital Management first reported a position in DFTX in Q4 2025 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Superstring Capital Management held 351,461 shares of Definium Therapeutics worth $6.64M as of Q1 2026.
  • Superstring Capital Management sold 73,741 Definium Therapeutics shares in Q1 2026, an estimated $1.25M.
  • Definium Therapeutics made up 4.75% of Superstring Capital Management's portfolio in Q1 2026, its #6 holding.
  • Superstring Capital Management first reported a position in Definium Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.